These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 11828001)

  • 1. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors.
    Heiser A; Coleman D; Dannull J; Yancey D; Maurice MA; Lallas CD; Dahm P; Niedzwiecki D; Gilboa E; Vieweg J
    J Clin Invest; 2002 Feb; 109(3):409-17. PubMed ID: 11828001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro.
    Heiser A; Dahm P; Yancey DR; Maurice MA; Boczkowski D; Nair SK; Gilboa E; Vieweg J
    J Immunol; 2000 May; 164(10):5508-14. PubMed ID: 10799919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients.
    Mu LJ; Kyte JA; Kvalheim G; Aamdal S; Dueland S; Hauser M; Hammerstad H; Waehre H; Raabe N; Gaudernack G
    Br J Cancer; 2005 Oct; 93(7):749-56. PubMed ID: 16136047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide.
    Perambakam S; Hallmeyer S; Reddy S; Mahmud N; Bressler L; DeChristopher P; Mahmud D; Nunez R; Sosman JA; Peace DJ
    Cancer Immunol Immunother; 2006 Sep; 55(9):1033-42. PubMed ID: 16283303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer.
    Su Z; Dannull J; Yang BK; Dahm P; Coleman D; Yancey D; Sichi S; Niedzwiecki D; Boczkowski D; Gilboa E; Vieweg J
    J Immunol; 2005 Mar; 174(6):3798-807. PubMed ID: 15749921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
    Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
    Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA.
    Heiser A; Maurice MA; Yancey DR; Wu NZ; Dahm P; Pruitt SK; Boczkowski D; Nair SK; Ballo MS; Gilboa E; Vieweg J
    J Immunol; 2001 Mar; 166(5):2953-60. PubMed ID: 11207244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer immunotherapy with mRNA-transfected dendritic cells.
    Gilboa E; Vieweg J
    Immunol Rev; 2004 Jun; 199():251-63. PubMed ID: 15233739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depletion of CD25+ cells from human T-cell enriched fraction eliminates immunodominance during priming with dendritic cells genetically modified to express a secreted protein.
    Mincheff M; Zoubak S; Altankova I; Tchakarov S; Pogribnyy P; Makogonenko Y; Botev C; Meryman HT
    Cancer Gene Ther; 2005 Feb; 12(2):185-97. PubMed ID: 15375382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells--a pilot study.
    Hildenbrand B; Sauer B; Kalis O; Stoll C; Freudenberg MA; Niedermann G; Giesler JM; Jüttner E; Peters JH; Häring B; Leo R; Unger C; Azemar M
    Prostate; 2007 Apr; 67(5):500-8. PubMed ID: 17262804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA.
    Barrou B; Benoît G; Ouldkaci M; Cussenot O; Salcedo M; Agrawal S; Massicard S; Bercovici N; Ericson ML; Thiounn N
    Cancer Immunol Immunother; 2004 May; 53(5):453-60. PubMed ID: 14760510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cell gene therapy.
    Onaitis M; Kalady MF; Pruitt S; Tyler DS
    Surg Oncol Clin N Am; 2002 Jul; 11(3):645-60. PubMed ID: 12487060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells.
    Su Z; Dannull J; Heiser A; Yancey D; Pruitt S; Madden J; Coleman D; Niedzwiecki D; Gilboa E; Vieweg J
    Cancer Res; 2003 May; 63(9):2127-33. PubMed ID: 12727829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors.
    Heiser A; Maurice MA; Yancey DR; Coleman DM; Dahm P; Vieweg J
    Cancer Res; 2001 Apr; 61(8):3388-93. PubMed ID: 11309297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.
    Gulley J; Chen AP; Dahut W; Arlen PM; Bastian A; Steinberg SM; Tsang K; Panicali D; Poole D; Schlom J; Michael Hamilton J
    Prostate; 2002 Oct; 53(2):109-17. PubMed ID: 12242725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
    Madan RA; Mohebtash M; Arlen PM; Vergati M; Rauckhorst M; Steinberg SM; Tsang KY; Poole DJ; Parnes HL; Wright JJ; Dahut WL; Schlom J; Gulley JL
    Lancet Oncol; 2012 May; 13(5):501-8. PubMed ID: 22326924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells.
    Nair SK; Morse M; Boczkowski D; Cumming RI; Vasovic L; Gilboa E; Lyerly HK
    Ann Surg; 2002 Apr; 235(4):540-9. PubMed ID: 11923611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
    Cappuccini F; Bryant R; Pollock E; Carter L; Verrill C; Hollidge J; Poulton I; Baker M; Mitton C; Baines A; Meier A; Schmidt G; Harrop R; Protheroe A; MacPherson R; Kennish S; Morgan S; Vigano S; Romero PJ; Evans T; Catto J; Hamdy F; Hill AVS; Redchenko I
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival.
    Thomas-Kaskel AK; Zeiser R; Jochim R; Robbel C; Schultze-Seemann W; Waller CF; Veelken H
    Int J Cancer; 2006 Nov; 119(10):2428-34. PubMed ID: 16977630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.